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Cervical cancer poses a substantial burden in terms of morbidity, mortality, and economic
losses, especially in low/middle-income countries. HPV vaccination and/or cervical cancer
screening among females may reduce the burden of HPV-related diseases, including cervi-
cal cancer. However, limited funds may impede the implementation of population-based
programmes. Governmental investments in the prevention of infectious disease may have
broader economic and fiscal benefits, which are not accounted in conventional economic
analyses. This study estimates the broader economic and fiscal impacts of implementing
HPV vaccination and/or cervical cancer screening in Indonesia from the perspective of the
government.
Methods
A government-perspective quantitative analytic framework was applied to assess the Net
Present Value (NPV) of investment on cervical cancer prevention strategies including HPV
vaccination, cervical screening and its combination in Indonesia. All monetary values were
presented in International Dollars (I$).
Results
Based on a cohort of 10,000,000 Indonesian 12-year-old females, it was estimated that
HPV vaccination and/or cervical cancer screening result in a positive NPV for the Indone-
sian government. The combination of cervical screening and HPV vaccination generated a
substantial reduction of cervical cancer incidence and HPV-related mortality of 87,862 and
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19,359, respectively. It was estimated that HPV vaccination in combination with cervical
screening is the most favorable option for cervical cancer prevention (NPV I
$2.031.786.000), followed by HPV vaccination alone (NPV I$1.860.783.000) and cervical
screening alone (NPV I$375.244.000).
Conclusion
In addition to clinical benefits, investing in HPV vaccination and cervical screening may
yield considerable fiscal benefits for the Indonesian governments due to lifelong benefits
resulting from reduction of cervical cancer-related morbidity and mortality.
Introduction
High-risk human papillomaviruses (hrHPV), in particular HPV16 and HPV18, are responsible
for cervical cancer and premalignant cervical disease among woman [1–5]. Although cervical
cancer is considered as a preventable disease when detected and managed in the early stages, it
still poses a serious health and economic burden, especially in developing countries [6–8]. The
WHO recommends primary prevention through vaccination against HPV and secondary pre-
vention through cervical screening for pre-cancerous lesions [9]. Numerous studies have
shown that cervical screening is beneficial in terms of lowering the incidence of pre-cancerous
lesions and cervical cancer [8,10,11]. Moreover, the two approved prophylactic vaccines against
HPV have also demonstrated considerable benefits in terms of reduction of HPV infection and
Cervical Intraepithelial Neoplasia (CIN) [9,12–15].
Several health-economic analyses have shown that HPV vaccination combined with cervical
cancer screening results in an efficient use of healthcare resources [16–19]. Such analyses typi-
cally assess the cost-effectiveness of adding HPV vaccination to screening. Hence, most eco-
nomic analyses focus on evaluating the technical efficiency of the healthcare budget [20].
Implementation of vaccination and cervical cancer screening programmes is dependent on
affordability and local infrastructure especially in low/middle-income countries, which have
limited infrastructure, human resources and funds. In low/middle-income countries, imple-
mentation of population-based HPV vaccination and screening programmes, such as VIA
screening which is suitable for low/middle-income countries, may require funds additional to
the healthcare budget. Hence, economic analyses should be capable of providing decision-mak-
ers with measures for the broader economic impact and cross-sectorial consequences of
resource allocation decisions.
HPV infection and cervical cancer disease pose a substantial morbidity and mortality bur-
den. In 2012, there were over 20,000 new cases of cervical cancer and 9,000 cervical-cancer
related deaths [7]. The implementation of a population-based HPV vaccination and/or VIA
screening programme requires a substantial investment, but it potentially reduces the burden
of cervical cancer. An additional benefits including more women who are able to work, more
women gain income [21–23], and on the government perspective, there will be more workers
who pay the taxes and health/social security premium. Notably, health-economic and broader
economic benefits including fiscal benefits for the Indonesian government could be achieved.
In this study, we assess the broader economic consequences of introducing HPV vaccination in
Indonesia with emphasis on the potential positive and negative fiscal effects of the latest policy
of the Indonesian National Social Security System (SJSN) for HPV prevention.
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Methods and Data
The natural history of cervical cancer for Indonesian women was modeled based on a previ-
ously published population-based Markov model [24]. The cervical cancer prevention strate-
gies, including HPV vaccination (3 doses of vaccination and 76.6% coverage) and/ or VIA
screening (every three years for 30–60 years old and 21.2% yearly coverage), were also adopted
from the same study. An additional strategy, HPV vaccination alone, was also added in the
analysis. This population-based Markov model was chosen given the scarce availability of data,
hampering the development of a more complex modeling approach. Several validation steps
were taken, including face validity checks for both the conceptual model and the input parame-
ters, extreme value testing and testing of traces.
The fiscal analysis described here simulates the natural history and costs of cervical cancer
patients in Indonesia. Susceptible, cervical cancer and death states were modeled and a simula-
tion was run for a cohort of 10,000,000 Indonesian 12-year-old girls over their lifetime [25,26].
Cervical cancer prevention strategies, that were assessed, included (i) cervical screening, (ii)
HPV vaccination and (iii) HPV vaccination plus cervical cancer screening. The reduction of
HPV-related morbidity and mortality resulting from each of the assessed strategies was quanti-
fied and translated into changes in age-specific gross tax revenue and government transfer
costs over the lifetime of the cohort. Specifically, based on previously published methods for
assessing of the broader economic consequences of health-care interventions [27–29], morbid-
ity and mortality reductions were translated into discounted, lifetime fiscal benefits for the
Indonesian government. Hence, prevention of HPV-related mortality and morbidity benefits
were converted into discounted lifetime (i) additional gross, direct and indirect tax revenues,
(ii) health-care cost savings and (iii) social insurance cost-savings. Fiscal expenses, i.e. the cost
of vaccination and the additional governmental transfers (i.e. pensions) resulting from the
additional survival produced by HPV prevention in Indonesia, were discounted and deducted
from the fiscal benefits of HPV prevention to produce the Net Present Value (NPV) of each
HPV prevention strategy.
In order to estimate the lifetime earnings and, thus, the lifetime tax revenues to be gained
from the average Indonesian female, earnings distribution was categorized into three levels
(20% high-income earners, 40% middle-income earners, and 40% low-income earners) and the
average of each earnings level, based on the Indonesian Gross Domestic Product (GDP) using
Gini index of 0.41 [30,31], was estimated. Furthermore, annual earnings were adjusted for
future productivity based on the labor productivity index from The Organization for Economic
Cooperation and Development (OECD) [32]. Earnings were also adjusted to reflect the propor-
tion of female workforce participation [25,33]. Moreover, the average age of entering the work-
force and the average retirement age of Indonesian civil servants were considered in the model
[34,35]. Direct tax was estimated based on the Indonesian earnings tax law [36,37] and applied
for each level of income. Thus, the model assumed that tax revenue stems from middle- and
high-income earnings only, since the average earnings of the low-income population lies below
the taxable earnings threshold. Indirect tax was estimated based on the Value Added Tax
(VAT) policy [38,39] and household consumption expenditure per capita [40]. Furthermore,
we assumed that VAT adherence and collectability rate was 50% [41] (Table 1).
Governmental transfers to citizens were estimated based on the national social and health
security system. The benefits provided by the social security system are pension funds, and
work-related accident and death-benefits [44,45]. Old-age pensions were estimated based as
60% of the earnings in the last employment year [48]. Direct costs related to pre-cancerous
lesions, cervical cancer and investment costs for prevention programs were included in the
model based on the study by Setiawan, et al. [24]. Costs were inflated to current prices using an
Assessment of HPV Prevention from a Government-Perspective
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Table 1. Model input Parameters.
Type Description value Comments Reference
National economic parameters Life expectancy 70.10 [42]
Gross Domestic Products (I$) 7,463 per capita [31]
Average Earnings(I$)
Low 3,183 as percentage of national GDP [30,31]
Middle 6,375 as percentage of national GDP [30,31]
High 18,198 as percentage of national GDP [30,31]
Retirement age 60 [35]
Annual inﬂation (%) 6.42 inﬂation rate [43]
Civil servant (%) 2.00 as percentage of female population [33]
Minimum age as a civil servant 18 [34]
Labor Productivity (%) 3.60 Yearly [32]
Discount rate (%) 3.00
Revenue Direct tax (%) based on Tax earnings bands
< I$6,390 0.00 as percentage of income [36,37]
I$6,390—I$13,150 5.00 as percentage of income [36,37]
I$13,150—I$65,748 15.00 as percentage of income [36,37]
Indirect tax
VAT (%) 10.00 value added tax [38,39]
Earnings consumed (I$) 1,960 household consumption expenditure per capita [40]
Tax adherence (%) 50.00 Assumption -
Social security
Pension fund beneﬁt (%)
Employee 2.00 as percentage of income [44,45]
Employer 3.70 as percentage of income [44,45]
Net revenue 47.10 after deducted by claim [46]
Work-related accident beneﬁt (%)
Employer 0.90 as percentage of income [44,45]
Net revenue 71.00 after deducted by claim [46]
Death beneﬁt (%)
Employer 0.30 as percentage of income [44,45]
Net revenue 60.00 after deducted by claim [46]
Membership of social security (%) 75.00 [47]
Health security (%) based on the participant's type
Employee (civil servants) 2.00 as percentage of income [44,45]
Employee (non-civil servants) 2.00 as percentage of income [44,45]
Employer (non-civil servants) 3.00 as percentage of income [44,45]
Membership of health security (%) 75.00 [47]
Expenditure Social security for civil servant (%) 6.00
Pension fund beneﬁt
Employer 3.70 as percentage of income [44,45]
Work related accident beneﬁt
Employer 0.90 as percentage of income [44,45]
Death beneﬁt
Employer 0.30 as percentage of income [44,45]
Death beneﬁt paid (I$) 5 per case [44,45]
Health security based on the participant's type
Poor people (I$) 5 per person [44,45]
Employer (%) 3.00 as percentage of income [44,45]
Pension Beneﬁt (%) 60.00 [48]
doi:10.1371/journal.pone.0160707.t001
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inflation rate of 6.42% which reflects the average inflation in 2014 [43]. Direct costs attributed
to genital warts have not been included in this analysis as they are likely to have limited fiscal
consequences in the context of treatment in Indonesia.
The discounted cash flow method was used to obtain the present value of cash inflows and
outflows. The results were presented in terms of the Net Present Value (NPV) of the invest-








NPVs were calculated by subtracting incremental expenses (Et), including vaccine cost at
t = 0 (K0) from incremental revenues (Rt) for each of strategy. Increments refer to the differ-
ence between the revenue and expenses with and without the HPV prevention strategy under
consideration. All values were discounted (r) by 3% according to WHO recommendation and
also consistent with previous cost-effectiveness studies on cervical cancer prevention pro-
grammes in Indonesia.
In order to examine the sensitivity of the model to its parameters, univariate sensitivity analyses
were conducted for the NPV of each HPV prevention strategy. The ranges around input parame-
ters including inflation rate, discount rate, Gross domestic products (GDP), tax compliance, mem-
bership of health and social security, percentage of earnings consumed and percentage of work-
related accident premium. Inflation and discount rates were varied by the lowest and highest value
of Indonesian inflation rate in 2014 [43] and acceptable discount rates from various countries [49],
respectively. The lower and upper limits for GDP were defined by the lowest and highest GDP
value of the previous 5 years [50], while the ranges for the proportion of earnings consumed were
based on previous 3 years’ data [51]. Tax compliance, health and social security membership were
varied based on assumptions since the distributions for this parameters were not available.
Results
Based on a single cohort of 10,000,000 girls in Indonesia, our model showed that in the absence
of any cervical cancer prevention strategy, 147,632 cases of cervical cancer will ultimately occur
within the cohort. The implementation of cervical cancer prevention strategies, including
screening alone, HPV vaccination alone, or cervical screening in combination with HPV vacci-
nation were projected to prevent 15,641, 80,750 or 87,862 cases of cervical cancer, respectively.
Furthermore, the combination of cervical screening and HPV vaccination generated the high-
est reduction of deaths caused by cervical cancer (19,359), followed by HPV vaccination alone
(17,541) and screening alone (4,005) (Table 2).
The lifetime NPV for the study cohort of Indonesian 12-year-old females is illustrated in
Table 3 for the three prevention strategies. All three strategies resulted in a positive NPV. HPV
vaccination in combination with cervical screening generates the highest NPV for the govern-
ment (I$2,031,786,000), followed by HPV vaccination only (I$1,860,783,000) and cervical
screening alone (I$375,244,000). Indirect tax produces the highest revenue for the government
Table 2. The impact of cervical cancer prevention strategies on incidence andmortality cases over a 58-years period.
Clinical Parameters No Intervention Screening Cervical Screening & HPV Vaccination HPV Vaccination
Cumulative incidence 147,632 131,991 59,770 66,882
Incremental incidence - 15,641 87,862 80,750
Cumulative mortality 32,046 28,041 12,687 14,505
Incremental mortality - 4,005 19,359 17,541
doi:10.1371/journal.pone.0160707.t002
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compared to direct tax, social- or health-security contributions. With respect to HPV-related
governments’ expenses, the highest saving is generated by treatment cost savings. HPV vacci-
nation in combination with cervical cancer screening results in the highest healthcare cost-sav-
ings. Similarly, the combined prevention strategy resulted in the highest savings in terms of
social security costs. All prevention strategies resulted in increased governments’ expenses in
terms of health security and pension costs.
Fig 1 illustrates the results of the univariate sensitivity analyses evaluating the influence of
several input parameters on the NPV. The analysis shows that inflation and discount rate are
the most influential parameters in this study [data not shown]. Further analysis illustrates that
NPV is also sensitive to GDP (as measure of earnings) and tax compliance. Health and social
Fig 1. Univariate sensitivity analysis for cervical cancer prevention strategies including cervical screening alone (A);
cervical screening and HPV vaccination (B); and HPV vaccination alone (C).
doi:10.1371/journal.pone.0160707.g001
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security membership, percentage of earnings consumed, and percentage of work-related acci-
dent premium are considered as non-influential parameters to the NPV.
Discussion
Implementation of population-based healthcare intervention unambiguously results in fiscal
costs due to changes in morbidity and mortality that influence national accounts over the life-
time of the cohort. However, similar to other public investments, investment in healthcare
interventions may also result in measurable, long-term fiscal benefits (i.e. tax revenue) attrib-
uted to changes in population health that may outweigh or considerably offset the costs [52].
In this study we evaluated how different levels of investment in HPV prevention influence the
Indonesian governments’ fiscal accounts. The study showed that investing in HPV vaccination
in combination with cervical screening yields long-term fiscal benefits for the Indonesian gov-
ernment. These results are supplementary to a previously published study on the cost-effective-
ness of cervical cancer prevention strategies in Indonesia [24]. Both studies suggest that
cervical cancer prevention strategies are not only beneficial for the health of Indonesian
women, they also improve the efficiency of healthcare resource use and have a long-term fiscal
benefit for the government by increasing the quality and quantity of the human capital and
thus by increasing the tax base in the country compared to not investing in HPV prevention.
The main clinical benefit of cervical cancer prevention programmes is the reduction of mor-
bidity and mortality [16,53–55]. In traditional health-economic analyses the comparative clini-
cal benefits and associated costs would be reflected in the incremental cost effectiveness ratio
(ICER) in terms of cost per quality-adjusted survival as a result of vaccination. The latter ratio
responds to the question of which is the most efficient use of healthcare resources for a given
healthcare budget. A cost-effectiveness analysis may also quantify productivity losses from pre-
mature mortality and/or absenteeism or presentism and thus reflect the benefits from a societal
perspective which are distinct from benefits accrued to government. In the model described
here we apply the tax burden to reflect the proportion of lifetime earnings that are transferred
to government to reflect fiscal benefits.
The underlying assumption of taking a broader economic analytic perspective with empha-
sis on fiscal effects is that changes in health status or the prevention of infectious diseases have
several external effects. The benefits of HPV prevention imply that more women who would be
able to work thus, gain more earnings and pay more taxes and security premiums for the gov-
ernment. As a result of this, it is expected that the prevention of HPV infection and HPV-
related diseases will yield increased governmental fiscal revenues from (direct and indirect)
taxes and also (health and social) security insurance premium. Moreover, there are significant
cost-savings resulting from reduced need for cervical cancer treatment which is captured in
conventional cost-effectiveness analyses and also demonstrated by application of a “govern-
ment-perspective” framework to assess different HPV investment strategies.
A key limitation of this type of study is that it is largely dependent on the mathematical
modeling of long-term clinical, economic and fiscal parameters. Although the population–
based model included high-quality clinical-trial data, including vaccine and VIA screening effi-
cacy on incidence and mortality, further model validation using observed-country-specific
data could still further assure the outcomes of the model. However, the Indonesia-specific
observational information is not available. Such further validation and comparing our model
with more sophisticated models from other countries with better data availability remains an
option for future research.
Some of the key parameters dynamically change over time in the real life. Sensitivity analy-
ses may address some of the uncertainty around these parameters. However, further
Assessment of HPV Prevention from a Government-Perspective
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observational data may be needed to assess the real-life fiscal effect of HPV prevention pro-
grammes. In addition, the current analysis does not take into account the effects of herd immu-
nity, inequalities in access to health-care services due to socio-economic and regional
differences, further distinctions in specific stages of both pre-cancer and cervical cancer, nor
the benefits that HPV vaccination may have in terms of (i) protection of males and (ii) preven-
tion of genital warts.
By conducting a broader economic analysis, evidence is produced to inform analyses
regarding the cross-sectorial allocation of resources and perhaps the transfer of funds from
other sectors of the public economy to universal population-based vaccination and screening
programmes. The evidence generated in this study may address the affordability of implement-
ing an HPV prevention program in Indonesia. Our study results suggest that investments in
HPV prevention programmes may generate epidemiological benefits that translate into health-
economic and fiscal benefits for the Indonesian government that may fully offset the invest-
ment costs and thus may have a positive impact on national accounts in the long-run.
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